fusion protein


Also found in: Dictionary, Thesaurus, Encyclopedia, Wikipedia.

fu·sion pro·tein

(fyū'zhŭn prō'tēn)
Biotechnologic product targeting malignant cells and some normal lymphocytes containing interleukin-2 (IL-2) receptors; used for treatment of patients with advanced and recurrent cutaneous T-cell lymphoma.
Medical Dictionary for the Health Professions and Nursing © Farlex 2012

fusion protein

A protein made from the natural or artificial hybridization and translation of two distinct genes.
See also: protein
Medical Dictionary, © 2009 Farlex and Partners

fusion protein

a hybrid recombinant PROTEIN that contains AMINO ACIDS coded for by the VECTOR DNA attached to the cloned GENE product.
Collins Dictionary of Biology, 3rd ed. © W. G. Hale, V. A. Saunders, J. P. Margham 2005
References in periodicals archive ?
Briefly, fusion proteins of glutathione S-transferase (GST) and the ligand binding domain (LBD) of the ER were bacterially expressed and partially purified on glutathione--Sepharose beads (Pharmacia, Piscataway, NJ).
"It is quite amazing how just one dose of the fusion protein was enough to induce significant tissue regeneration in two weeks" says the paper's lead author Piyush Koria.
The fusion proteins retained full antibody binding and cytokine activity, and combinations of the anti-PS antibody linked to the different cytokines had better anti-tumor effects than either agent alone, inhibiting tumor growth by over 90% in some B-cell lymphoma and melanoma tumor models.
IDELVION, the company's novel, long-acting recombinant albumin fusion protein, is an factor IX therapy that delivers zero median AsBR (annualised spontaneous bleeding rate) and is approved for up to 14-day dosing in appropriate patients.
"The protection of our proprietary CoVal fusion proteins is a priority at Nventa," said Gregory M.
Clover is using Trimer-Tag(c) technology to create trimerized fusion proteins that are able to effectively target these previously undruggable pathways.
This fusion protein targets common regulatory mechanisms in different types of chronic pain, and has unique properties as demonstrated by UMCU researchers, who showed that it is effective in reducing pain in multiple pre-clinical models.
Vicinium, a locally-administered fusion protein, is Sesen Bio's lead product candidate being developed for the treatment of high-risk non-muscle invasive bladder cancer (NMIBC).
Vicinium is a locally-administered targeted fusion protein composed of an anti-EPCAM antibody fragment tethered to a truncated form of Pseudomonas Exotoxin A for the treatment of high-risk NMIBC.
TAK-169 is a first-in-class CD38-targeted fusion protein and the milestone payment reportedly relates to BioInvent's proprietary n-CoDeR antibody library and its role in the discovery of the investigational compound.
Production of target protein as a fusion protein increases the efficiency of its soluble expression in E.